270 related articles for article (PubMed ID: 33220458)
1. Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance.
Fatma H; Maurya SK; Siddique HR
Semin Cancer Biol; 2022 Aug; 83():166-176. PubMed ID: 33220458
[TBL] [Abstract][Full Text] [Related]
2. MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance.
Marengo B; Garbarino O; Speciale A; Monteleone L; Traverso N; Domenicotti C
Oxid Med Cell Longev; 2019; 2019():7346492. PubMed ID: 31341534
[TBL] [Abstract][Full Text] [Related]
3. Deterministic Somatic Cell Reprogramming Involves Continuous Transcriptional Changes Governed by Myc and Epigenetic-Driven Modules.
Zviran A; Mor N; Rais Y; Gingold H; Peles S; Chomsky E; Viukov S; Buenrostro JD; Scognamiglio R; Weinberger L; Manor YS; Krupalnik V; Zerbib M; Hezroni H; Jaitin DA; Larastiaso D; Gilad S; Benjamin S; Gafni O; Mousa A; Ayyash M; Sheban D; Bayerl J; Aguilera-Castrejon A; Massarwa R; Maza I; Hanna S; Stelzer Y; Ulitsky I; Greenleaf WJ; Tanay A; Trumpp A; Amit I; Pilpel Y; Novershtern N; Hanna JH
Cell Stem Cell; 2019 Feb; 24(2):328-341.e9. PubMed ID: 30554962
[TBL] [Abstract][Full Text] [Related]
4. Identification of the specific epigenetic alterations associated with chemo-resistance via reprogramming of cancer cells.
Kim JJ; Rai R
Med Hypotheses; 2015 Dec; 85(6):710-4. PubMed ID: 26527497
[TBL] [Abstract][Full Text] [Related]
5. MYC in oncogenesis and as a target for cancer therapies.
Albihn A; Johnsen JI; Henriksson MA
Adv Cancer Res; 2010; 107():163-224. PubMed ID: 20399964
[TBL] [Abstract][Full Text] [Related]
6. Emerging roles of Myc in stem cell biology and novel tumor therapies.
Yoshida GJ
J Exp Clin Cancer Res; 2018 Jul; 37(1):173. PubMed ID: 30053872
[TBL] [Abstract][Full Text] [Related]
7. Application of iPS cell technology to cancer epigenome study: uncovering the mechanism of cell status conversion for drug resistance in tumor.
Matsuda Y; Semi K; Yamada Y
Pathol Int; 2014 Jul; 64(7):299-308. PubMed ID: 25047500
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic reprogramming and potential application of epigenetic-modifying drugs in acquired chemotherapeutic resistance.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Adv Clin Chem; 2020; 94():219-259. PubMed ID: 31952572
[TBL] [Abstract][Full Text] [Related]
9. Gene Transactivation and Transrepression in MYC-Driven Cancers.
Scafuro M; Capasso L; Carafa V; Altucci L; Nebbioso A
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801599
[No Abstract] [Full Text] [Related]
10. A Versatile In Vivo System to Study Myc in Cell Reprogramming.
Senís E; Mosteiro L; Grimm D; Abad M
Methods Mol Biol; 2021; 2318():267-279. PubMed ID: 34019296
[TBL] [Abstract][Full Text] [Related]
11. Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.
Allen-Petersen BL; Sears RC
BioDrugs; 2019 Oct; 33(5):539-553. PubMed ID: 31392631
[TBL] [Abstract][Full Text] [Related]
12. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state.
Poli V; Fagnocchi L; Fasciani A; Cherubini A; Mazzoleni S; Ferrillo S; Miluzio A; Gaudioso G; Vaira V; Turdo A; Gaggianesi M; Chinnici A; Lipari E; Bicciato S; Bosari S; Todaro M; Zippo A
Nat Commun; 2018 Mar; 9(1):1024. PubMed ID: 29523784
[TBL] [Abstract][Full Text] [Related]
13. NCoR/SMRT co-repressors cooperate with c-MYC to create an epigenetic barrier to somatic cell reprogramming.
Zhuang Q; Li W; Benda C; Huang Z; Ahmed T; Liu P; Guo X; Ibañez DP; Luo Z; Zhang M; Abdul MM; Yang Z; Yang J; Huang Y; Zhang H; Huang D; Zhou J; Zhong X; Zhu X; Fu X; Fan W; Liu Y; Xu Y; Ward C; Khan MJ; Kanwal S; Mirza B; Tortorella MD; Tse HF; Chen J; Qin B; Bao X; Gao S; Hutchins AP; Esteban MA
Nat Cell Biol; 2018 Apr; 20(4):400-412. PubMed ID: 29531310
[TBL] [Abstract][Full Text] [Related]
14. Attacking c-Myc: targeted and combined therapies for cancer.
Huang H; Weng H; Zhou H; Qu L
Curr Pharm Des; 2014; 20(42):6543-54. PubMed ID: 25341931
[TBL] [Abstract][Full Text] [Related]
15. Insights into the Links between MYC and 3D Chromatin Structure and Epigenetics Regulation: Implications for Cancer Therapy.
Amjadi-Moheb F; Paniri A; Akhavan-Niaki H
Cancer Res; 2021 Apr; 81(8):1925-1936. PubMed ID: 33472888
[No Abstract] [Full Text] [Related]
16. Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again!
Wooten DJ; Quaranta V
Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):167-175. PubMed ID: 28396217
[TBL] [Abstract][Full Text] [Related]
17. DNA Damage Signaling-Induced Cancer Cell Reprogramming as a Driver of Tumor Relapse.
Filipponi D; Emelyanov A; Muller J; Molina C; Nichols J; Bulavin DV
Mol Cell; 2019 May; 74(4):651-663.e8. PubMed ID: 30954402
[TBL] [Abstract][Full Text] [Related]
18. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
[TBL] [Abstract][Full Text] [Related]
19. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
[TBL] [Abstract][Full Text] [Related]
20. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.
Savino M; Annibali D; Carucci N; Favuzzi E; Cole MD; Evan GI; Soucek L; Nasi S
PLoS One; 2011; 6(7):e22284. PubMed ID: 21811581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
